GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Haemonetics Corp (FRA:HAZ) » Definitions » E10

Haemonetics (FRA:HAZ) E10 : €0.87 (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Haemonetics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Haemonetics's adjusted earnings per share data for the three months ended in Dec. 2023 was €0.559. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €0.87 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Haemonetics's average E10 Growth Rate was 22.80% per year. During the past 3 years, the average E10 Growth Rate was 5.80% per year. During the past 5 years, the average E10 Growth Rate was 2.50% per year. During the past 10 years, the average E10 Growth Rate was -5.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Haemonetics was 17.20% per year. The lowest was -15.30% per year. And the median was 3.70% per year.

As of today (2024-05-05), Haemonetics's current stock price is €86.50. Haemonetics's E10 for the quarter that ended in Dec. 2023 was €0.87. Haemonetics's Shiller PE Ratio of today is 99.43.

During the past 13 years, the highest Shiller PE Ratio of Haemonetics was 223.42. The lowest was 27.14. And the median was 87.73.


Haemonetics E10 Historical Data

The historical data trend for Haemonetics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haemonetics E10 Chart

Haemonetics Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.58 0.63 0.59 0.56 0.76

Haemonetics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.72 0.76 0.85 0.89 0.87

Competitive Comparison of Haemonetics's E10

For the Medical Instruments & Supplies subindustry, Haemonetics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Haemonetics's Shiller PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Haemonetics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Haemonetics's Shiller PE Ratio falls into.



Haemonetics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Haemonetics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.559/129.4194*129.4194
=0.559

Current CPI (Dec. 2023) = 129.4194.

Haemonetics Quarterly Data

per share eps CPI Adj_EPS
201403 0.137 99.695 0.178
201406 -0.052 100.560 -0.067
201409 0.109 100.428 0.140
201412 0.251 99.070 0.328
201503 -0.055 99.621 -0.071
201506 -0.009 100.684 -0.012
201509 0.223 100.392 0.287
201512 -1.074 99.792 -1.393
201603 -0.155 100.470 -0.200
201606 -0.178 101.688 -0.227
201609 0.339 101.861 0.431
201612 0.284 101.863 0.361
201703 -0.920 102.862 -1.158
201706 0.338 103.349 0.423
201709 0.319 104.136 0.396
201712 -0.101 104.011 -0.126
201803 0.178 105.290 0.219
201806 -0.043 106.317 -0.052
201809 0.300 106.507 0.365
201812 0.308 105.998 0.376
201903 0.354 107.251 0.427
201906 -0.150 108.070 -0.180
201909 0.654 108.329 0.781
201912 0.522 108.420 0.623
202003 0.317 108.902 0.377
202006 0.186 108.767 0.221
202009 0.798 109.815 0.940
202012 0.510 109.897 0.601
202103 -0.185 111.754 -0.214
202106 -0.075 114.631 -0.085
202109 0.247 115.734 0.276
202112 0.398 117.630 0.438
202203 0.173 121.301 0.185
202206 0.359 125.017 0.372
202209 0.646 125.227 0.668
202212 0.604 125.222 0.624
202303 0.532 127.348 0.541
202306 0.738 128.729 0.742
202309 0.450 129.860 0.448
202312 0.559 129.419 0.559

Add all the adjusted EPS together and divide 10 will get our e10.


Haemonetics  (FRA:HAZ) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Haemonetics's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=86.50/0.87
=99.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Haemonetics was 223.42. The lowest was 27.14. And the median was 87.73.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Haemonetics E10 Related Terms

Thank you for viewing the detailed overview of Haemonetics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Haemonetics (FRA:HAZ) Business Description

Traded in Other Exchanges
Address
125 Summer Street, Boston, MA, USA, 02110
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Haemonetics (FRA:HAZ) Headlines

No Headlines